<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464526</url>
  </required_header>
  <id_info>
    <org_study_id>ORV-ADP-01</org_study_id>
    <nct_id>NCT03464526</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis</brief_title>
  <acronym>SOOTHE</acronym>
  <official_title>A Double-Blind, Randomised, Placebo Controlled Study of the Efficacy and Safety and Pharmacokinetics of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nerre Therapeutics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nerre Therapeutics Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of three doses of orvepitant,&#xD;
      taken once a day, in the treatment of pruritus associated with atopic dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center, double-blind, randomized, parallel group, placebo-controlled dose range study&#xD;
      in subjects with pruritus associated with atopic dermatitis.&#xD;
&#xD;
      Doses of orvepitant (10 mg/day, 20 mg/day and 30 mg/day) and placebo will be investigated in&#xD;
      four parallel groups.&#xD;
&#xD;
      Each group will compromise of approximately 100 subjects, randomized 1:1:1:1 (approximately&#xD;
      400 subjects in total).&#xD;
&#xD;
      All subjects will enter a two-week screening period to determine eligibility. Eligible&#xD;
      subjects will be randomized at the Baseline/Day 1 visit and enter a 12-week double-blind&#xD;
      dosing period. During this period there will be four visits at Weeks 2, 4, 8 and 12. There&#xD;
      will be a final safety follow-up visit four weeks after the end of the treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Strategic decision&#xD;
  </why_stopped>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Itch Intensity - Numeric Rating Scale</measure>
    <time_frame>Week 12</time_frame>
    <description>Change from baseline in the mean worst NRS pruritus intensity scores recorded by the subject during the last 3 days of available values in the period prior to the week 12 visit</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pruritus</condition>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Orvepitant 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orvepitant 10mg tablet, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orvepitant 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orvepitant 20mg tablet, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orvepitant 30mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orvepitant 30mg tablet, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet, once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orvepitant</intervention_name>
    <description>Tablet, once daily, oral</description>
    <arm_group_label>Orvepitant 10mg</arm_group_label>
    <arm_group_label>Orvepitant 20mg</arm_group_label>
    <arm_group_label>Orvepitant 30mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, once daily, oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of Atopic Dermatitis for ≥ 6 months confirmed by either the UK&#xD;
             Working Party definition or the Hanifin definition&#xD;
&#xD;
          -  Subjects must have chronic (&gt; 6 months) pruritus which is unresponsive or inadequately&#xD;
             responsive to current therapies such as topical steroids or antihistamines&#xD;
&#xD;
          -  Subjects must have atopic dermatitis with a severity &gt; 3 on the IGA and EASI ≥12 at&#xD;
             Screening visit/Visit 1&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Presence of, or history of, any other inflammatory dermatosis or skin conditions which&#xD;
             may cause pruritus&#xD;
&#xD;
          -  Any other possible cause for pruritus eg systemic, neurological, idiopathic, or&#xD;
             metabolic&#xD;
&#xD;
          -  Acute super-infection of AD lesions requiring treatment with antibiotics within 4&#xD;
             weeks of Visit 2&#xD;
&#xD;
          -  Inability to comply with the use of prohibited and allowed medications as described in&#xD;
             the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

